Imagion Biosystems Ltd (ASX: IBX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Imagion Biosystems Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$10.79 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
490.59 million
Earnings per share
-0.016
Dividend per share
N/A
Year To Date Return
-12.00%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Imagion Biosystems Ltd (ASX: IBX)
Latest News
Healthcare Shares
The Imagion Biosystems (ASX:IBX) share price just exploded by 60%. Here's why
Share Gainers
The Imagion Biosystems (ASX:IBX) share price leapt 40% in 2 days this week. What's happening?
Healthcare Shares
Imagion Biosystems (ASX:IBX) share price soars 13% on quarterly update
Share Gainers
Imagion (ASX:IBX) share price zips 38% higher. Here's why
Healthcare Shares
Imagion (ASX:IBX) share price up 1,166% in a year pursuing 'radiation-free' cancer tech
IBX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Imagion Biosystems Ltd
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.
IBX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 02 Apr 2026 | $0.02 | $0.00 | 0.00% | 1,829,111 | $0.02 | $0.02 | $0.02 |
| 01 Apr 2026 | $0.02 | $0.00 | 0.00% | 830,395 | $0.02 | $0.02 | $0.02 |
| 31 Mar 2026 | $0.02 | $0.00 | 0.00% | 1,087,028 | $0.02 | $0.02 | $0.02 |
| 30 Mar 2026 | $0.02 | $0.00 | 0.00% | 1,327,451 | $0.02 | $0.02 | $0.02 |
| 27 Mar 2026 | $0.02 | $0.00 | 0.00% | 80,121 | $0.02 | $0.02 | $0.02 |
| 26 Mar 2026 | $0.02 | $0.00 | 0.00% | 3,952,958 | $0.02 | $0.02 | $0.02 |
| 25 Mar 2026 | $0.02 | $0.00 | 0.00% | 1,489,664 | $0.02 | $0.02 | $0.02 |
| 24 Mar 2026 | $0.02 | $0.00 | 0.00% | 4,485,313 | $0.02 | $0.02 | $0.02 |
| 23 Mar 2026 | $0.02 | $0.00 | 0.00% | 4,120,987 | $0.02 | $0.02 | $0.02 |
| 20 Mar 2026 | $0.02 | $0.00 | 0.00% | 388,859 | $0.02 | $0.02 | $0.02 |
| 19 Mar 2026 | $0.02 | $0.00 | 0.00% | 508,650 | $0.02 | $0.02 | $0.02 |
| 18 Mar 2026 | $0.02 | $0.00 | 0.00% | 527,758 | $0.02 | $0.02 | $0.02 |
| 17 Mar 2026 | $0.02 | $0.00 | 0.00% | 712,289 | $0.02 | $0.02 | $0.02 |
| 16 Mar 2026 | $0.02 | $0.00 | 0.00% | 1,105,248 | $0.02 | $0.02 | $0.02 |
| 13 Mar 2026 | $0.02 | $0.00 | 0.00% | 883,455 | $0.02 | $0.02 | $0.02 |
| 12 Mar 2026 | $0.02 | $0.00 | 0.00% | 1,288,426 | $0.02 | $0.02 | $0.02 |
| 11 Mar 2026 | $0.02 | $0.00 | 0.00% | 974,595 | $0.02 | $0.02 | $0.02 |
| 10 Mar 2026 | $0.02 | $0.00 | 0.00% | 352,292 | $0.02 | $0.02 | $0.02 |
| 09 Mar 2026 | $0.02 | $0.00 | 0.00% | 1,251,815 | $0.02 | $0.02 | $0.02 |
| 06 Mar 2026 | $0.02 | $0.00 | 0.00% | 1,914,668 | $0.02 | $0.02 | $0.02 |
| 05 Mar 2026 | $0.02 | $0.00 | 0.00% | 952,459 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 29 Dec 2025 | Robert Proulx | Exercise | 1,400,000 | $30,800 |
Conversion of securities. 600,000 rights
|
| 29 Dec 2025 | Robert Proulx | Issued | 1,400,000 | $30,800 |
Conversion of securities.
|
| 26 Sep 2025 | Robert Proulx | Issued | 1,666,667 | $68,333 |
Issue of options.
|
| 26 Sep 2025 | Robert Proulx | Issued | 1,666,667 | $25,000 |
Issue of securities.
|
| 26 Sep 2025 | Brett Mitchell | Issued | 1,666,667 | $68,333 |
Issue of options.
|
| 26 Sep 2025 | Brett Mitchell | Issued | 1,666,667 | $25,000 |
Issue of securities.
|
| 16 Sep 2025 | Nina Webster | Buy | 565,211 | $20,303 |
On-market trade.
|
| 10 Jul 2025 | Robert Proulx | Issued | 2,000,000 | $38,000 |
Issue of options.
|
| 10 Jul 2025 | Brett Mitchell | Issued | 2,000,000 | $38,000 |
Issue of options. As per announcement on 17-07-2025
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Melanie Jaye Leydin | Company Secretary Non-Execufive Director | May 2024 |
Ms Leydin is now the Executive Vice President of Global Solutions, Southeast Asia at Vistra. Vistra is a provider of governance and compliance solutions and finance and accounting solutions in the Fund, Corporate, Capital Markets, and Private Wealth sectors. Ms Leydin is now the Executive Vice President of Global Solutions, Southeast Asia at Vistra. Vistra is a provider of governance and compliance solutions and finance and accounting solutions in the Fund, Corporate, Capital Markets, and Private Wealth sectors. Ms Leydin has over 30 years of experience in the accounting profession and over 20 years of experience holding Board positions. Ms Leydin has experience in relation to public company responsibilities, including control and implementation of corporate governance, statutory financial reporting, reorganization of Companies, initial public offerings, secondary raisings and shareholder relations.
|
| Mr Brett Anthony Mitchell | Non-Executive Director | Jun 2024 |
Mr Mitchell is an experienced corporate finance executive with more than 15 years of experience leading transactions in the biopharmaceutical, mining, energy and tech industries. He has been involved in the founding, financing, and management of both private and publicly listed companies. Additionally, Mr Mitchell has founded two financial advisory services businesses.
|
| Dr Nina Webster | Non-Executive Director | Sep 2025 |
Dr Webster brings experience in investor relations, strategic planning, and scientific and operational execution. Dr Webster currently also serves as Non-Executive Chairperson for SYNthesis BioVentures and as Non-Executive Director for Linear Clinical Research Limited.
|
| Mr Robert Romeo Proulx | Executive DirectorExecutive Chairman | Dec 2016 |
Mr Proulx's career spans more than 30 years with experience in the computer, life science and medical diagnostics industries.
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Irh Pty Ltd | 12,020,329 | 2.45% |
| Mr Andrew Jones | 12,000,000 | 2.45% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 11,997,378 | 2.44% |
| Celtic Finance Corp Pty Ltd | 10,400,000 | 2.12% |
| Mr Lakhwinder Singh | 10,215,248 | 2.08% |
| Mr Robert Farah | 10,000,000 | 2.04% |
| Citicorp Nominees Pty Limited | 9,762,898 | 1.99% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 8,521,306 | 1.74% |
| Mr Senhao Miao | 7,450,000 | 1.52% |
| Zerrin Investments Pty Ltd | 6,000,000 | 1.22% |
| Mr Brett Mitchell & Mrs Michelle Mitchell <Lefthanders Super Fund A/C> | 5,937,575 | 1.21% |
| Scintilla Strategic Investments Limited | 5,333,334 | 1.09% |
| Mr Hyungjae Park | 5,100,000 | 1.04% |
| Kevrex Pty Ltd <Kevrex Investment A/C> | 4,522,494 | 0.92% |
| Mr Robert Proulx | 4,470,749 | 0.91% |
| Longreach 52 Pty Ltd | 4,042,521 | 0.82% |
| Mr Marcus Antonius Hendrikus Kennis & Mr Stuart Dean Roberts <Sweet Freedom A/C> | 3,666,667 | 0.75% |
| Exit Out Pty Ltd <The Discretionary A/C> | 3,666,666 | 0.75% |
| Mrs Sharon Lewis | 3,550,000 | 0.72% |
| Nysha Investments Pty Ltd <Sanghavi Family A/C> | 3,458,378 | 0.70% |